Telsey Advisory Group analyst Dana Telsey maintains Allbirds (NASDAQ:BIRD) with a Outperform and lowers the price target from $9 to $7.
Immuneering Announces $30M Underwritten Offering Of 2,727,273 Shares Of Common Stock At A Price Of $11/Share
Immuneering Corporation (NASDAQ:IMRX) ("Immuneering"), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy,
